We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
+11.29%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$231M
AUM Growth
-$69.8M
Cap. Flow
-$84.5M
Cap. Flow %
-36.53%
Top 10 Hldgs %
95.34%
Holding
23
New
–
Increased
5
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
EOLS icon
Evolus
EOLS
+$1.38M
2
ADMA icon
ADMA Biologics
ADMA
+$438K
3
ALIM
Alimera Sciences
ALIM
+$53.3K
4
XERS icon
Xeris Biopharma Holdings
XERS
+$39.9K
5
AYTU icon
AYTU BioPharma
AYTU
+$275

Top Sells

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$19.9M
2
QDEL icon
QuidelOrtho
QDEL
+$14.1M
3
MXCT icon
MaxCyte
MXCT
+$11.7M
4
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$8.2M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$5.75M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EOLS icon
1
Evolus
EOLS
$598M
$56.2M 24.29%
5,333,004
+154,000
+3% +$1.38M
ADMA icon
2
ADMA Biologics
ADMA
$2.15B
$41.7M 18.03%
9,222,617
+118,342
+1% +$438K
AMLX icon
3
Amylyx Pharmaceuticals
AMLX
$3.78B
$36.8M 15.92%
2,500,000
-15,868
-0.6% -$243K
QDEL icon
4
QuidelOrtho
QDEL
$955M
$33.2M 14.34%
450,000
-208,794
-32% -$14.1M
ALIM
5
DELISTED
Alimera Sciences
ALIM
$17.3M 7.47%
3,999,459
+15,773
+0.4% +$53.3K
XERS icon
6
Xeris Biopharma Holdings
XERS
$1.57B
$14M 6.03%
5,937,000
+21,628
+0.4% +$39.9K
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$10.6M 4.6%
261,870
-540,674
-67% -$19.9M
XOMA
8
DELISTED
Xoma
XOMA
$4.63M 2%
250,000
-186,602
-43% -$3.07M
IOBT
9
DELISTED
IO Biotech
IOBT
$3.13M 1.35%
1,666,037
-309,271
-16% -$369K
SCYX icon
10
SCYNEXIS
SCYX
$53.2M
$3.02M 1.31%
169,398
-187,177
-52% -$2.75M
RZLT icon
11
Rezolute
RZLT
$437M
$2.75M 1.19%
2,768,656
-303,820
-10% -$279K
AVIR icon
12
Atea Pharmaceuticals
AVIR
$467M
$2.56M 1.11%
839,514
-880,486
-51% -$2.67M
TELA icon
13
TELA Bio
TELA
$35.1M
$2.1M 0.91%
317,782
-174,137
-35% -$1.01M
AYTU icon
14
AYTU BioPharma
AYTU
$24.5M
$1.34M 0.58%
472,469
+100
+0% +$275
XGN icon
15
Exagen
XGN
$183M
$1.33M 0.58%
669,684
-533,807
-44% -$923K
ATYR
16
aTyr Pharma
ATYR
$49.4M
$680K 0.29%
482,258
-4,144,366
-90% -$5.32M
ASRT
17
DELISTED
Assertio
ASRT
– –
-63,413
Closed -$2.44M
DCTH icon
18
Delcath Systems
DCTH
$572M
– –
-686,240
Closed -$2.78M
GOSS icon
19
Gossamer Bio
GOSS
$85.8M
– –
-3,339,405
Closed -$2.78M
MXCT icon
20
MaxCyte
MXCT
$130M
– –
-3,761,640
Closed -$11.7M
VNDA icon
21
Vanda Pharmaceuticals
VNDA
$323M
– –
-477,903
Closed -$2.06M
XFOR icon
22
X4 Pharmaceuticals
XFOR
$401M
– –
-175,790
Closed -$5.75M
GMDA
23
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-7,965,865
Closed -$8.2M

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Stonepine Capital Management held 23 positions worth $231M, down 23% from $301M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Stonepine Capital Management withdrew a net $84.5M in Q4 2023, closing 7 positions and reducing 11 holdings. Its most notable exit was MaxCyte, an estimated $11.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Stonepine Capital Management added an estimated $1.38M to Evolus.

  • Stonepine Capital Management added most to Evolus in Q4 2023, an estimated $1.38M increase.
  • Stonepine Capital Management's biggest Q4 2023 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $19.9M.
  • Stonepine Capital Management fully exited MaxCyte in Q4 2023, selling an estimated $11.7M.
  • Stonepine Capital Management's ten largest holdings make up 95% of its $231M portfolio in Q4 2023.
  • Stonepine Capital Management opened 0 new positions and closed 7 in Q4 2023.
  • Stonepine Capital Management's portfolio value fell 23% quarter-over-quarter to $231M.

Based on Stonepine Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.